Press Archive

ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference

ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics

ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics

ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225

ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177

ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023

ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer

ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities

ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer

ITM Appoints Roger Estafanos as U.S. General Manager and Expands Presence with Opening of U.S. Headquarters in Princeton, New Jersey

ITM lädt zu Symposium und Messestand auf der Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin in Leipzig ein

ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference

ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma

ITM to Present at the 41st Annual J.P. Morgan Healthcare Conference

ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)

ITM: Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177

ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors

ITM Multiplies Production Capacity for its n.c.a. Lutetium-177

ITM and BAMF Health Enter Global Cooperation Agreement for Targeted Radiopharmaceuticals in U.S. Radiopharmacy and Clinic Network

ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022

ITM Acquires a New Platform for the Development of Next-Generation Theranostics

ITM Appoints Dr. Sebastian Marx as Chief Business Officer and Member of Executive Board

ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177

ITM: New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope

ITM to Host Symposium on Actinium-225 Targeted Radionuclide Therapy and to Present Phase III COMPOSE Trial Design at the Theranostics World Congress

ITM to Host Scientific Precision Oncology Symposium in Parallel to the ASCO Annual Meeting on Friday, June 03, 2022

ITM kündigt Symposium und Präsenz auf der 60. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin in Leipzig an

ITM and MTTI Sign Clinical Supply Agreement for n.c.a. Lutetium-177

ITM Announces Successful Completion of Patient Recruitment for its Phase III Trial, COMPETE, with Lead Radiotherapeutic ITM-11 (n.c.a. lutetium-177-edotreotide)

ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer

ITM Receives EUR 33 Million Equity Investment to Advance Precision Oncology Pipeline of Targeted Radiopharmaceuticals

ITM to Support Educational Symposium on Multi-disciplinary Approaches to Personalized Medicine at the 2022 SNMMI Therapeutics Conference

ITM Presents Design of Second Phase III Trial, COMPOSE, with Radiopharmaceutical ITM-11 for the Treatment of Neuroendocrine Tumors at Annual ENETS Conference 2022

ITM Receives Equity Investment of EUR 25 Million from Strategic Partner Grand Pharma

ITM Announces Key Appointments to its U.S. Leadership Team

ITM Announces First Patient Treated in Second Phase III Trial, COMPOSE, with ITM-11 (n.c.a. lutetium-177-edotreotide) for Treatment of Neuroendocrine Tumors

ITM: Installation of New Isotope Production System at Bruce Power to Produce Medical Isotopes for Cancer Therapy Completed

ITM Announces First Patient Treated in Second Phase III Trial, COMPOSE, with ITM-11 (n.c.a. lutetium-177-edotreotide) for Treatment of Neuroendocrine Tumors

ITM Presents Study Design of COMPOSE Phase III Trial with ITM-11 (n.c.a. lutetium-177-edotreotide) for Treatment of Neuroendocrine Tumors at ASCO-GI

ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme

ITM Isotope Technologies Munich to Present at the 40th Annual J.P. Morgan Healthcare Conference

ITM and Grand Pharma Enter into a Commercialization Agreement for Targeted Radiopharmaceuticals in the Greater China Area

ITM and ANSTO Announce Extension of Licensing Agreement for the Production and Supply of the Medical Radioisotope n.c.a. Lutetium-177

ITM and Navigo Proteins Announce Research Collaboration to Develop FAP-targeting Radionuclide Therapy to Address Solid Tumors

ITM Introduces Second Phase III Trial, COMPOSE, with n.c.a. Lutetium-177-Edotreotide for Neuroendocrine Tumors at NANETS Annual Symposium 2021

ITM and Clovis Oncology Announce Lutetium-177 Clinical Supply Agreement

ITM and CNL Sign Memorandum of Understanding to Pursue Global Development and Production of Rare Medical Radioisotope, Actinium-225

ITM Announces Completion of Conversion into SE

ITM and Chengdu Gaotong Isotope Co. Ltd. Form Joint Venture to Expand Access to ITM’s Diagnostic and Therapeutic Radioisotopes in China

ITM Announces Completion of Conversion into SE

ITM to Host Virtual Symposium at the ESMO Congress 2021 with Key Neuroendocrine Tumor Experts on September 17, 2021

ITM Appoints Dr. Sabine Daugelat as Chief Operating Officer

ITM Appoints Dr. Klaus Maleck as Chief Financial Officer

ITM Announces EUR 25 Million (USD 30 M) Private Equity Financing to Support Advancement of Proprietary Precision Oncology Pipeline

ITM to Host Virtual Symposium on “New Approaches for Targeted Radionuclide Therapy in Precision Oncology” with Key Opinion Leaders on Friday, June 4th, 2021 in Parallel to 2021 ASCO Annual Meeting

ITM Precision Oncology Symposium in parallel to the 2021 ASCO Annual Meeting

ITM establishes subsidiary in Shanghai to accelerate introduction of its precision oncology portfolio in China

ITM raises EUR 90 M (USD 109 M) to accelerate precision oncology pipeline and support ongoing phase 3 clinical program

ITM Presents Design for Ongoing Phase III COMPETE Trial with n.c.a. 177Lu-Edotreotide at AACR Annual Meeting 2021

ITM Enters Global Supply Agreements with Telix Pharmaceuticals for Clinical and Commercial Use of ITM’s n.c.a. Lutetium-177

ITM announces poster presentation outlining the ongoing phase III GEP-NET trial COMPETE at AACR Annual Meeting 2021

FDA has issued Drug Master File for ITM’s Gallium Generator GeGant®

EANM 2020: ITM emphasizes commitment to developing Targeted Radionuclide Therapies with satellite symposium on bone metastases

Agreement signed to advance Lutetium-177 isotope production to meet global demand for critical cancer-fighting therapies

Agreement signed to advance Lutetium-177 isotope production to meet global demand for critical cancer-fighting therapies

Invitation ITM Satellite Symposium @ Virtual EANM 2020

Bruce Power and IsoGen set first critical milestone for exclusive irradiation service provided to ITM for its production of no-carrier-added Lutetium-177

ITM and RadioMedix announce Drug Master File Submission for ITM’s ⁶⁸Ge/⁶⁸Ga Generator GeGant^® for the U.S. Market.

ITM and POINT Biopharma sign two supply agreements for no-carrier-added Lutetium-177

English summary of the Süddeutsche Zeitung Article about ITM "Zielgenau gegen Krebszellen" - "Fighting Cancer with Pinpoint Precision"

Rebranding: ITG Isotope Technologies Garching GmbH will become ITM Medical Isotopes GmbH

ITM expands PSMA-617 supply agreement for no-carrier-added Lutetium-177

European Investment Bank provides funding of €40 million to ITM

ITM receives German Medical Award 2019 for the most innovative product

ITM and CIRC sign technology license agreement for the production and distribution of medical radioisotopes in China

Bruce Power, ITM and partners finalize agreement paving way for new medical isotope delivery system expected in 2022

ITM signs long-term supply agreements with Nordic Nanovector for no-carrier-added Lutetium-177

ITM erhält Förderbescheid der Bayerischen Forschungsstiftung

ITM and Bruce Power successfully complete feasibility study

Mona M Wahba joins ITM as Deputy Chief Medical Officer

ITM and DCB sign exclusive Licensing & Development Agreement for Solucin® TRT in South Korea while COMPETE clinical trial sees strong growth in recruitment numbers in the U.S.

Michael Lee-Chin joins the ITM Supervisory Board

ITM builds new production site in Munich Area

ITM and United Imaging team up in strategic partnership to cover Chinese and global cancer imaging markets

ITM receives Pharma Trend Award 2018 "Most Innovative Product"

ITM and Merck sign Research Evaluation and Option Agreement to develop Folate Receptor Targeted Radionuclide Therapy

RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.

Endocyte and ITM announce Long-Term Supply Agreement for no-carrier-added Lutetium-177

Bruce Power joins forces with ITM to supply Lutetium-177 for cancer therapy

FDA Acceptance of IND to advance Phase III Clinical Trial COMPETE with Solucin® for Treatment of GEP-NET in the U.S.

ITM announces appointment of Philip E. Harris as new Chief Medical Officer

Marketing Authorization for TOCscan® (68Ga-Edotreotide) in Germany, Austria and France

ITM Isotopen Technologien München AG chosen as a 2018 Red Herring Top 100 Europe Winner

ITM Isotopen Technologien München AG unterzeichnet Charta der Vielfalt

Endocyte and ITM announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial

First gastroenteropancreatic-neuroendocrine tumor (GEP-NET) patient in Europe for the COMPETE phase III clinical trial with n.c.a. 177Lu-Edotreotide (Solucin®)

Successful Hosting of the Investigator Meeting for Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET

ITM as Front-Runner in the Life Sciences Industry of the Germany’s fastest growing Technology Companies

First Patient in Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin) in Cancer Patients with GEP-NET

ITM´s subsidiary ITG receives Drug Approval for EndolucinBeta®

EMA/CHMP adopts positive opinion for ITM’s EndolucinBeta®

ITM and Scil Proteins announce new Partnership for Targeted Radio Conjugates

ITM announces successful fundraising of 20 million EUR

Isotope Technologies Garching GmbH announces in- licensing of DOTA-Zoledronate for Bone Targeted Radionuclide Theranostics of Osseous Metastases